John B Moriarty
First SEC filing: Nov. 18, 2020 · Latest: Nov. 18, 2020
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 17, 2026 | KARD | A | 47,784 | · | · | 47,784 Direct | · | Acquired | (price as of 2026-10-02) |
| Feb. 27, 2026 | RNA | D | 160,000 | · | · | 0 Direct | -100.00% | Disposed | |
| Feb. 27, 2026 | RNA | D | 50,000 | · | · | 0 Direct | -100.00% | Disposed | |
| Feb. 27, 2026 | RNA | D | 92,054 | · | · | 0 Direct | -100.00% | Disposed | |
| Jan. 7, 2026 | RNA | S 10b5-1 | 2,374 | $72.23 | $171,474 | 74,557 Direct | -3.09% | Disposed | |
| Dec. 17, 2025 | RNA | A | 56,000 | · | · | 103,755 Direct | +117.27% | Acquired | |
| Dec. 17, 2025 | RNA | F | 26,824 | $71.87 | $1,927,841 | 76,931 Direct | -25.85% | Disposed | |
| Aug. 4, 2025 | RNA | S 10b5-1 | 2,245 | $36.21 | $81,291 | 47,755 Direct | -4.49% | Disposed | |
| Jan. 6, 2025 | RNA | A | 25,000 | · | · | 50,000 Direct | +100.00% | Acquired | |
| Jan. 6, 2025 | RNA | A | 50,000 | · | · | 50,000 Direct | · | Acquired | |
| Aug. 1, 2024 | RNA | A | 25,000 | · | · | 25,000 Direct | · | Acquired | |
| Aug. 1, 2024 | RNA | A | 160,000 | · | · | 160,000 Direct | · | Acquired | |
| Feb. 1, 2023 | OLMA | A | 150,000 | · | · | 150,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Feb. 1, 2022 | OLMA | A | 166,250 | · | · | 166,250 Direct | · | Acquired | (price as of 2026-10-02) |
| Nov. 18, 2020 | OLMA | A | 161,406 | · | · | 161,406 Direct | · | Acquired | (price as of 2026-10-02) |
| Sept. 19, 2020 | OLMA | A | 252,060 | · | · | 252,060 Direct | · | Acquired | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Feb. 27, 2026 | RNA | Stock Option (Right to Buy) | Common Stock | $44.57 | July 31, 2034 | 160,000 | Disposed |
| Feb. 27, 2026 | RNA | Stock Option (Right to Buy) | Common Stock | $31.42 | Jan. 5, 2035 | 50,000 | Disposed |
| Jan. 6, 2025 | RNA | Stock Option (Right to Buy) | Common Stock | $31.42 | Jan. 5, 2035 | 50,000 | Acquired |
| Aug. 1, 2024 | RNA | Stock Option (Right to Buy) | Common Stock | $44.57 | July 31, 2034 | 160,000 | Acquired |
| Feb. 1, 2023 | OLMA | Stock Option (Right to Buy) | Common Stock | $4.87 | Jan. 31, 2033 | 150,000 | Acquired |
| Feb. 1, 2022 | OLMA | Stock Option (Right to Buy) | Common Stock | $7.02 | Jan. 31, 2032 | 166,250 | Acquired |
| Nov. 18, 2020 | OLMA | Stock Option (Right to Buy) | Common Stock | $19.00 | Nov. 17, 2030 | 161,406 | Acquired |
| Sept. 19, 2020 | OLMA | Stock Option (Right to Buy) | Common Stock | $4.82 | Sept. 18, 2030 | 252,060 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 2 holdings
Securities held when first becoming an insider, per SEC Form 3.
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
CIK 1599901
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2024 | $208,333 | · | $4,226,090 | $5,081,184 | $168,800 | · | $14,789 | $9,699,196 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.